Maria T Kopicki, MD | |
65 Country Corners Rd, Amherst, MA 01002-3317 | |
(413) 256-2316 | |
Not Available |
Full Name | Maria T Kopicki |
---|---|
Gender | Female |
Speciality | Obstetrics & Gynecology |
Location | 65 Country Corners Rd, Amherst, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659565166 | NPI | - | NPPES |
3185958 | Medicaid | MA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 157586 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Maria T Kopicki, MD 65 Country Corners Rd, Amherst, MA 01002-3317 Ph: (413) 256-2316 | Maria T Kopicki, MD 65 Country Corners Rd, Amherst, MA 01002-3317 Ph: (413) 256-2316 |
News Archive
Kaiser Health News staff writers Phil Galewitz and Jordan Rau report: "Offering the latest tough-love strategy to reduce the nation's debt, a panel of high-profile Republicans and Democrats is scheduled on Wednesday to recommend that Medicare beneficiaries pick up far more of their health care costs and the government substantially curb the amount both Medicare and Medicaid programs can grow in future years" (Galewitz and Rau, 11/16).
The idea that insights from the healthcare systems of low-income countries might be transferable from low to high-income countries is becoming increasingly common in global health and innovation publications.
Scientists at the University of York have shown that altering the structure of sugar chains on the surface of stem cells could help promote bone growth in the body.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists say that the decrease in severity of manic symptoms is the attribute that most influences their prescribing decisions in bipolar mania. Clinical data and the opinions of interviewed thought leaders indicate that Eli Lilly's Zyprexa (olanzapine) has advantages in this attribute over AstraZeneca/Astellas's Seroquel (quetiapine), the sales-leading agent in the bipolar disorder drug market.
› Verified 7 days ago